Home > Healthcare > Pharmaceuticals > Finished Drug Form > Pigmentation Disorder Treatment Market

Pigmentation Disorder Treatment Market Analysis

  • Report ID: GMI8528
  • Published Date: Mar 2024
  • Report Format: PDF

Pigmentation Disorder Treatment Market Analysis

Based on the treatment type, the global market is classified into drugs and procedures. The drugs segment is further bifurcated into type, route of administration, and end users. The segment dominated the market with revenue of USD 4 billion in 2023.

  • The segmental growth is owing to increased research and development activities and product launches by major players in the industry. For instance, in July 2022, Ahammune Biosciences formed a partnership with Veeda Clinical Research Limited to conduct clinical trials for AB1001, a drug therapy for vitiligo. This collaboration aims to advance the development of topical treatments and is expected to bolster the growth of the dermatology drugs in the foreseeable future.
  • Further, administration of corticosteroids is highly recommended for treating pigmentation disorders. Betamethasone valerate, fluticasone propionate, and hydrocortisone butyrate are frequently used corticosteroids. Thus, availability of wide range of drugs in the market is expected to spur the segment growth.
Pigmentation Disorder Treatment Market, By Type of Disorder (2023)

Based on type of disorder, the pigmentation disorder treatment market is classified into hypopigmentation and hyperpigmentation. The hypopigmentation segment is divided into Vitiligo, Albinism, and other hypopigmentations, whereas the hyperpigmentation segment is divided into Melasma, Lentigines, post-inflammatory hyperpigmentation (PIH) and other hyperpigmentations.

  • The hypopigmentation segment is expected to exhibit CAGR of 6.1% between 2024 – 2032 period.
  • Albinism is a rare set of genetic disorders characterized by reduced or absent pigmentation in the skin, hair, or eyes. The high segmental growth is primarily due to the increasing prevalence of albinism. For instance, as per an article published in August 2022 by StatPearls, it was disclosed that the American region exhibited the significant occurrence of oculocutaneous albinism type 2, with a prevalence rate of 1 in 36,000. Thus, with the increasing prevalence of albinism, the surge in demand for treatments targeting pigmentation disorders is expected to spur the growth of this segment.
North America Pigmentation Disorder Treatment Market, 2020 – 2032 (USD Billion)

In 2023, North America region held a market share of 42.2% in the global pigmentation disorder treatment market and is expected to dominate throughout the forecast period.

  • High regional market growth can be attributed to the high healthcare expenditure, advanced healthcare infrastructure in the region, and increase in the skin procedures are contributing to the demand for pigmentation disorder treatment.
  • For instance, according to data from the Aesthetic Plastic Surgery National Databank in April 2022, the U.S. recorded about 1.3 million skin treatment procedures in 2021, which included hydro facials, chemical peels, and others. This high incidence of cosmetics is expected to drive regional growth.
  • Additionally, the presence of prominent market players and extensive research and development activities in the region, further drive market expansion.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global pigmentation disorders treatment market was valued at USD 7.1 billion in 2023 and is expected to reach USD 11.6 billion by 2032, backed by the increasing prevalence of pigmentation disorders, such as vitiligo, melasma, and post-inflammatory hyperpigmentation among others.

The drugs segment accounted USD 4 billion in 2023 and will record notable demand through 2032, owing to increased R&D activities and product launches by major players in the industry.

In 2023, North America pigmentation disorders treatment market share was around 42.2%, and is expected to show impressive growth through 2032, attributed to high healthcare expenditure, alongside advanced medical infrastructure in the region.

AbbVie Inc., Candela Corporation, Cipher Pharmaceuticals Inc., Galderma, GlaxoSmithKline (GSK), Incyte, L'Oréal Paris, Novartis AG, Pfizer Inc., Pierre Fabre Group, and Shiseido Company Limited among others.

Pigmentation Disorder Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 192
  • Countries covered: 19
  • Pages: 125
 Download Free Sample